Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(20%)
Results Posted
100%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_3
2
40%
Ph phase_1
1
20%
Ph early_phase_1
1
20%
Ph phase_2
1
20%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (20.0%)
Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)

Trials by Status

terminated120%
active_not_recruiting120%
unknown240%
completed120%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_2

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

NCT03937830
completedphase_3

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT01004978
unknownearly_phase_1

Role of DEB-TACE Versus c-TACE in Treatment of HCC

NCT05093920
terminatedphase_1

Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

NCT01009801
unknownphase_3

Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

NCT01324076

Clinical Trials (5)

Showing 5 of 5 trials
NCT03937830Phase 2

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Active Not Recruiting
NCT01004978Phase 3

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Completed
NCT05093920Early Phase 1

Role of DEB-TACE Versus c-TACE in Treatment of HCC

Unknown
NCT01009801Phase 1

Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

Terminated
NCT01324076Phase 3

Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5